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Background: Since 2011, artesunate + sulphadoxine-pyrimethamine (ASP), instead of chloroquine, has been
recommended for treatment of uncomplicated malaria in India. In Ujjain, central India, with an annual parasite
index <0.1, the prevalence of drug-resistant Plasmodium falciparum is unknown. In other parts of India chloroquine
and sulphadoxine-pyrimethamine-resistant P. falciparum is prevalent. The aim of this study was to determine the
prevalence of anti-malarial drug resistance-associated genetic polymorphisms in P. falciparum collected in Ujjain in
2009 and 2010, prior to the introduction of ASP.
Methods: Blood samples from 87 patients with P. falciparum mono-infection verified by microscopy were collected
on filter-paper at all nine major pathology laboratories in Ujjain city. Codons Pfcrt 72–76, pfmdr1 1034–1246, pfdhfr
16–185, pfdhps 436–632 and pfnhe1 ms4760 haplotypes were identified by sequencing. Pfcrt K76T and pfmdr1 N86Y
were identified by restriction fragment length polymorphism, and pfmdr1 gene copy number by real-time PCR.
Results: Sulphadoxine-pyrimethamine resistance-associated pfdhfr 108 N and 59R alleles were found in 75/78 (96%)
and 70/78 (90%) samples, respectively, and pfdhps 437G was found in 7/77 (9%) samples. Double mutant pfdhfr
59R + 108 N were found in 62/76 (82%) samples. Triple mutant pfdhfr 59R + 108 N and pfdhps 437G were found
in 6/76 (8%) samples. Chloroquine-resistance-associated pfcrt 76 T was found in 82/87 (94%). The pfcrt 72–76
haplotypes found were: 80/84 (95%) SVMNT, 3/84 (4%) CVMNK and 1/84 (1%) CVMNT. Pfmdr1 N86 and 86Y were
identified in 70/83 (84%) and 13/83 (16%) samples, respectively. Pfmdr1 S1034 + N1042 + D1246 were identified
together in 70/72 (97%) of successfully sequenced samples. One pfmdr1 gene copy was found in 74/75 (99%)
successfully amplified samples.
Conclusion: This is the first characterization of key anti-malarial drug resistance-associated genetic markers
among P. falciparum collected in Ujjain, Madhya Pradesh, India. The results indicate that the efficacy of standard
dose chloroquine at the time of the study was likely to be poor, whereas ASP was likely to be efficacious, supporting
the changed drug treatment policy. However, P. falciparum with reduced susceptibility to sulphadoxine-pyrimethamine
is highly prevalent, highlighting the need for continuous surveillance of ASP efficacy in the study area.
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Approximately 85% of India’s population of 1.2 billion
people live in malarious areas and transmission inten-
sities vary from unstable to hyperendemic [1,2]. In 2012
there were 1.3 million reported malaria cases in India,
although the true burden is probably considerably higher
[2,3]. Furthermore, the proportion of the more virulent
Plasmodium falciparum has increased in recent years
and now accounts for 49% of the total malaria burden
[2,4]. Since 2011 the Directorate of National Vector Born
Disease Control Programme recommends that verified un-
complicated P. falciparummalaria and severe malaria should
be treated with artesunate plus sulphadoxine-pyrimethmine
(ASP) and quinine, respectively. Chloroquine (CQ) was the
official first line drug prior to 2011. However, in areas with
known CQ resistance, sulphadoxine-pyrimethmine (SP), be-
tween 1982 and 2005 and from 2005 ASP were recom-
mended for treatment of uncomplicated malaria instead of
CQ [4]. High grade SP resistance is widespread in parts of
Southeast Asia and artemisinin resistance is developing
along the Thai-Cambodia and Thai-Myanmar borders
[5-7]. Furthermore, the PCR-corrected day 42 ASP fail-
ure rate was 9.5% (5/53) in a recent study from West
Bengal [8]. There is thus a need to monitor AS-SP effi-
cacy throughout India.
SP resistance in P. falciparum has been linked to single
nucleotide polymorphisms (SNPs) A16V, C50R, N51I, C59R,
S108N/T and I164L in dihydrofolate reductase (pfdhfr) and
SNPs S436A/F, A437G, K540E, A581G and A613S in dihy-
dropteroate synthase (pfdhps) [9-14]. Accumulation of SNPs
typically starting with S108N leads to gradual reduction of
susceptibility to SP and increased risk of treatment failure
[15]. The quintuple pfdhfr 51I + 59R + 108N and pfdhps
437G+ 540E haplotype is highly predictive of SP treatment
failure in Africa [16]. In line with this, ASP treatment failures
in West Bengal occurred in patients with pfdhfr 51I + 59R +
108N and pfdhps 437G or 436A+ 540E [8]. These SNP
combinations have also been reported from Odisha (eastern
India) and the triple pfdhfr 59R + 108N+ 164L haplotype
has been reported from the northeastern state of Assam
[17,18]. Moreover, quadruple pfdhfr 51I + 59R+ 108N+
164L and pfdhps with three or four resistance-associated
SNP combinations are common on the Andaman and
Nicobar islands (Bay of Bengal) [19-21].
Resistance to CQ has developed in only five geo-
graphical locations but has spread from these points of
origin to encompass most of the malaria endemic world
[7,22]. A K76T SNP in the P. falciparum CQ resistance
transporter gene (pfcrt) is essential for CQ resistance
and this has been found at high frequencies through-
out India [23-27]. Typically 76T is found together
with additional SNPs creating specific pfcrt 72–76
haplotypes that indicate the origin of CQ resistance
[22]. The pfcrt 72–76 haplotypes SVMNT from PapuaNew Guinea and CVIET from Southeast Asia are pre-
dominant in India [17,28].
In addition to these well-characterized, resistance-causing
SNPs, P. falciparum multidrug resistance gene (pfmdr1) and
sodium/hydrogen exchanger gene (pfnhe1) have been asso-
ciated with anti-malarial drug resistance: Pfmdr1 N86Y,
S1034C, N1042D and D1246Y have been suggested to
modulate levels of CQ resistance [29,30]. Increased
pfmdr1 copy number has been linked to reduced sus-
ceptibility to artemisinin derivatives, lumefantrine, piper-
aquine and mefloquine as well as artesunate +mefloquine
treatment failure [31-34]. Pfmdr1 N86 and pfcrt K76 have
been linked to reduced lumefantrine susceptibility [35-37].
Pfmdr1 S1034C, N1042D and D1246Y, >1 DNNND re-
peats and one DDNHNDNHNND repeat in the coding
microsatellite ms4760 of pfnhe1 have been linked to re-
duced quinine sensitivity [29,38,39].
Monitoring the frequency of P. falciparum resistance-
associated genetic polymorphisms thus has the potential
to identify declining susceptibility to a number of anti-
malarial drugs. In Ujjain district located in Madhya
Pradesh, central India, CQ was used until 2011 when
ASP was introduced but no data on drug susceptibility
of P. falciparum in the area exists. This study therefore
analysed key anti-malarial resistance-associated genetic
markers prior to the introduction of ASP for the first
time. The report provides baseline data indicating a
probable high efficacy of ASP and facilitates future
monitoring of changing prevalence of resistance-
associated genetic polymorphisms in this region as
well as for comparisons with neighbouring areas.
Methods
Study site and period
Ujjain district is located in the western part of Madhya
Pradesh, central India. The population of the district is
1.9 million as per 2011 Census [40]. The climate is trop-
ical and transmission may occur throughout the year
provided the relative humidity levels support the vector
survival. Ujjain district has low transmission of malaria
with annual parasite index (API) <0.1 in 2010 [41]. Peak
malaria transmission occurs during the warm and humid
months of July to September. Data collection was, there-
fore, done from June to October in 2009 and 2010.
Recruitment of patients and sample collection
Samples and data were collected by the nine major path-
ology laboratories located in Ujjain city, Madhya
Pradesh, India. Individuals or groups of pathologists with
a postgraduate degree in pathology reported the results
from participating laboratories. All laboratories used
microscopical examination of peripheral blood smear for
the diagnosis of P. falciparum malaria. The only inclu-
sion criterion was microscopically verified malaria. For
Table 1 The number and frequency of resistance-associated
pfdhfr and pfdhps alleles in Plasmodium falciparum samples
collected Ujjain, Madhya Pradesh, India in 2009 and 2010
Pfdhfr A16V N51I C59R S108N I164L
Sensitive 69/69 78/78 8/78 (10%) 3/78 (4%) 78/78
Resistant 0/69 0/78 70/78 (90%) 75/78 (96%) 0/78
Pfdhps S436F A437G K540E A581G A613T
Sensitive 0/76 70/77 (91%) 77/77 77/77 77/77
Resistant 76/76 7/77 (9%) 0/77 0/77 0/77
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of blood was put onto filter papers (Whatman™ 3MM).
The filter papers were labelled with the patient’s age and
sex, dried and then placed inside individual sealed plastic
bags.
Sample storage, DNA extraction
Filter papers were stored at room temperature. DNA
was extracted using QIAamp Blood Mini Kit (QIAgen
Biosciences, Germantown, MD, USA) according to the
manufacturer’s instructions. Extracted DNA was stored
at −20°C until use.
Molecular analyses
Pfcrt 72–76, pfmdr1 1034–1246, pfdhfr 16–185, pfdhps
436–632 and pfnhe1 ms4760 haplotypes were identified
by PCR amplification followed by sequencing using
previously described PCR protocols [23,37,42-44]. The
Sequencher™ software version 4.6 (Gene Codes Corporation,
Ann Arbor, MI, USA) was used for sequencing analysis. The
P. falciparum 3D7 clone sequences obtained from NCBI
database was used as references for pfcrt (Accession no
NC_004328), pfmdr1 (Accession no XM_001351751.1),
pfdhfr (Accession no XM_001351443.1) and pfdhps (Acces-
sion no XM_001349382.1). Pfnhe1 ms4760 sequences were
compared with previously described isolates and clones.
In addition, previously described multiplex PCR-
RFLP (restriction fragment length polymorphism) methods
were used to identify pfcrt K76T and pfmdr1 N86Y
SNPs [23,45,46].
PCR and restriction products were resolved on 2% agar-
ose gels (Amresco, Solon, OH, USA). All gels were stained
with a nucleic acid gel stain (GelRed™, Biotium Inc,
Hayward, CA, USA) and visualized under UV transillu-
mination (GelDoc®, Biorad, Hercules, CA, USA). PCR
products were purified and sequenced commercially
(Macrogen Inc, Seoul, Korea).
Pfmdr1 copy numbers were determined using real time
PCR (ABI Prism® 7000 Sequence Detection System). Real
time PCR reactions were run in triplicate for each sample
as previously described [47]. P. falciparum strains
3D7, D10 and K1 with single copies of the pfmdr1 gene
were used as calibrators and FCB and Dd2 strains with
multiple copies of the gene were used as controls. The
sample copy numbers were calculated using a com-
parative threshold method (ΔΔCT). Assays were re-
peated if the following results were obtained: copy
number 1.3-1.6 and 2.3-2.6 or CT value >35 or stand-
ard deviation value >0.5. Samples with repeated CT
values >35 were considered to have failed.
Statistical analyses
The exact incidence of P. falciparum malaria was not
known and we therefore decided to collect as manysamples as possible over a two year period. SNP fre-
quencies were calculated by dividing the number of SNPs
by the number of patients in whom a certain the allele
could be identified. Allele frequencies in 2009 and 2010
were compared using Chi-squared tests.
Ethics
Patients with uncomplicated malaria were enrolled and
samples collected after informed oral consent of the pa-
tient or in the case of minors informed proxy-consent of
their parent or guardian. The study was approved by the
Institutional Ethics Committee of R D Gardi Medical
College in Ujjain, Madhya Pradesh, India (61/2009) and
the Regional Ethics Committee in Stockholm, Sweden
(2011/832-32/2).
Results
During the peak malaria seasons 2009 and 2010, 44 and 43
(total 87) patients with microscopically verified P. falcip-
arum mono-infection were identified and included. The
median age was 30 years (inter quartile range 15–30 years).
Forty-four patients were male and 34 female, for the
remaining nine individuals sex was not recorded. PCR was
successful for at least one allele in all 87 samples. There
were no significant differences in SNP frequencies between
2009 and 2010.
Pfdhfr and pfdhps
The number of resistance-associated SNPs and haplo-
types are shown in Tables 1 and 2. The resistance-
associated pfdhfr 108N and 59R alleles were found in
75/78 (96%) 70/78 (90%) samples, respectively. No sam-
ple had resistance-associated SNPs at codons 16, 50, 51
or 164. Pfdhfr 108N and 59R alleles were found together
in 70/78 (90%) of samples.
The resistance-associated pfdhps 437G allele was found
in 7/77 (9%) samples. No resistance-associated alleles were
detected at codons 540, 581 or 613. All samples (76/76)
carried the resistance-associated 436F allele.
Combined pfdhfr and pfdhps haplotypes were identi-
fied in 76 samples. Double mutant pfdhfr 59R + 108N
were found in 62/76 (82%) samples and double mutant
pfdhfr 108N and pfdhps 437G was found in 1/76 (1%)
Table 2 The number and frequency of pfdhfr and pfdhps resistance-associated haplotypes in Plasmodium falciparum
samples collected in Ujjain, Madhya Pradesh, India in 2009 and 2010
No of each haplotype No SNPs* Pfdhfr Pfdhps
51 59 108 164 436 437 540 581 613
3 (4%) 1 N C S I F A K A A
4 (5%) 2 N C N I F A K A A
1 (1%) 3 N C N I F G K A A
62 (82%) 3 N R N I F A K A A
6 (8%) 4 N R N I F G K A A
2 2 N R N I
1 1 F A K A A
Resistance associated alleles are written in bold and are italics.
*Number of resistance-associated SNPs in each haplotype.
Haplotype proportions were calculated from the total number (76) of samples in which both pfdhfr and pfdhps haplotypes were identified.
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437G were found in 6/76 (8%) samples. All these haplo-
types also had the 436 F allele potentially adding one
resistance-associated SNP to each haplotype.
Pfcrt
Pfcrt 76T was found in 82/87 (94%) and pfcrt K76 was
found in 5/87 (6%) of samples. The pfcrt 72–76 haplotypes
found were: 80/84 (95%) SVMNT, 3/84 (4%) CVMNK and
1/84 (1%) CVMNT. Sequencing failed altogether in three
samples and identified only the pfcrt 72–75 haplotype in
13 samples. In these 13 samples, the 76 allele was detected
using PCR-RFLP (Table 3).
Pfmdr1
Pfmdr1 N86 and 86Y were identified in 70/83 (84%) and
13/83 (16%) samples, respectively. Pfmdr1 86Y only oc-
curred together with pfcrt 76 T. Pfmdr1 S1034 + N1042
were identified together in all 75 successfully sequenced
samples. Pfmdr1 D1246 and 1246Y were identified in
70/72 (97%) and 2/72 (3%) samples, respectively. No
sample had the pfmdr1 1226Y allele associated with re-
duced sensitivity to artemisinin, lumefantrine and meflo-
quine [48].
One pfmdr1 gene copy was found in 74/75 (99%) suc-
cessfully amplified samples. After repeating PCRs three
times, one sample had two pfmdr1 copies and six sam-
ples had an indeterminate number of copies with ΔΔCt
(cycle threshold) values consistently between 1.3 and 1.6.
PCRs failed in six samples primarily due to CT values
above the 35-cycle cut-off. Further details are shown in
Table 3.
Pfnhe1
The numbers of DNNND and DDNHNDNHNND repeats
in pfnhe1 ms4760 were identified in 74/87 (85%) samples
(Table 3). Five previously described pfnhe1 ms4760 profiles
were detected at the following frequencies: ms4760-1(n = 4), ms4760-2 (n = 14), ms4760-5 (n = 7), ms4760-6
(n = 46), ms4760-7 (n = 3). More than one DNNND re-
peat was found in 60/74 (81%) samples. The numbers
of DDNHNDNHNND repeats were one in 56/74 (76%)
and two in 18/74 (24%) of samples. The numbers of re-
peats were not associated with any SNP or haplotypes
in pfcrt, pfmdr1, pfdhfr or pfdhps.
Discussion
This is the first characterization of key anti-malarial
drug resistance associated genetic polymorphisms among
P. falciparum field isolates in Ujjain, Madhya Pradesh,
central India. Importantly, this study was conducted prior
to implementation of artemisinin-based combination ther-
apy (ACT) in Ujjain and thus provides baseline data on
the prevalence of resistance-associated polymorphisms
prior to the introduction of ASP. From these data the
prevalence of in vivo CQ and SP resistance in the study
area can be inferred. The data also provide baseline infor-
mation for future temporal surveillance of resistance-
associated genetic polymorphisms in the study area as well
as for comparisons with neighbouring areas.
Despite this study being conducted prior to the intro-
duction of ASP, the SP resistance-associated 436F allele
was found in all samples. This is an allele that has previ-
ously been described in several Indian states and that
has been found to modulate SP susceptibility [21]. Typ-
ically, SP resistance arises through sequential selection
of SNPs, starting with pfdhfr 108 N and 59R followed by
SNPs in pfdhps [15]. It is thus most likely that 436F is a
wild type allele in Ujjain. Nevertheless, it may well result
in a degree of reduced susceptibility to SP [12].
The majority (82%) of samples in this study carried the
SP resistance-associated double pfdhfr 59R and 108N
together with pfdhps 436F. This suggests a moderate
degree of reduced susceptibility to SP and a low risk of
treatment failure at the time of the study. Furthermore,
only one sample had two pfmdr1 gene copies that have
Table 3 The number and frequency of pfcrt, pfmdr1 and pfnhe ms 4760 alleles in Plasmodium falciparum field samples
collected in Ujjain, Madhya Pradesh, India in 2009 and 2010
Gene Polymorphism/no of repeats Number/total* Proportion (%)
Pfcrt 76 K 5/87 6
T 82/87 94
Pfmdr1
86 N 70/83 84
86 Y 13/83 16
1034 + 1042 SN 75/75 100
1246 D 70/72 97
1246 Y 2/72 3
Gene copy number† 1 74/75 99
2 1/75 1








* Total number of polymorphisms successfully identified at each locus.
†Pfmdr1 gene copy number was between one and two (ΔΔCt 1.3-1.6) in six samples and PCRs failed in six samples.
All pfmdr1 86Y occurred together with pfcrt 76 T. Pfmdr1 1246Y alleles occurred together with pfcrt 76 T and pfmdr1 N86.
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on these findings, it is likely that ASP is highly effica-
cious for treatment of uncomplicated P. falciparum mal-
aria in Ujjain. However, four samples had pfdhfr 59R +
108N and pfdhps 436F + 437G indicating that these
parasite subpopulations only need to acquire one more
SNP in pfdhfr to become similar to P. falciparum that
was associated with treatment failure in nearby West
Bengal (pfdhfr 51I + 59R + 108N and pfdhps 437G or
436A + 540E) [8]. This is particularly concerning consid-
ering that this report is based on data collected before
ASP was introduced in Ujjain.
Of even greater concern, previous experience suggests
that SP resistance can and will spread rapidly despite the
concurrent use of artesunate. Specifically, the prevalence of
the quintuple DHFR +DHPS haplotype increased from 11
to 75% after only four years of using ASP in Mozambique
[49]. Furthermore, CQ resistance swept across India and
SP resistance spread through Southeast Asia in the past
[50]. The existence of highly SP-resistant P. falciparum on
the Andaman and Nicobar islands as well as in north-
eastern India is, therefore, worrisome [18-21]. Spread of SP
resistance will in turn expose artesunate to a high selective
pressure, which may spur development and spread of new
foci of decreased susceptibility to artemisinin. This high-
lights the need for continual monitoring of drug resistance
in Ujjain as well as the rest of India.
The 95% prevalence of pfcrt 76T in Ujjain is similar to
data from many other parts of India as well as neighbouringcountries such as Pakistan [51,52]. The high prevalence sug-
gests that treatment failure rates following intake of a total
dose of 25 mg/kg of CQ are likely to be similar to the ~70%
treatment failure rate reported from Goa in 2011, when the
76T prevalence was 100% [53]. In view of the high preva-
lence of pfcrt 76T, replacing CQ was undoubtedly the cor-
rect decision also for Ujjain. Sequencing of the pfcrt 72–76
haplotype identified the typical CQ “wild type” CVMNK
haplotype associated with CQ sensitivity in the three pa-
tients that had K76. In patients harbouring the 76T allele,
the principle haplotype found was SVMNT. This is the most
common haplotype in India as well as Pakistan, Iran and
probably originates from Papua New Guinea [17,51,52,54].
In addition, haplotype CVMNT that has also been described
previously in India, was found [53]. Thus the pfcrt SNPs
found in Ujjain are the same as in most of India in line
with previous studies showing how CQ resistance spread
throughout the country.
Given the proximity and similar genetic background of
CQ-resistant P. falciparum in India and Pakistan it is
likely that the genetic mechanism causing resistance is
similar. It is therefore noteworthy that changing the CQ
dosing schedule to 40 mg/kg as divided doses over five
days compared to the standard 25 mg/kg over three days
approximately doubled the efficacy of CQ (49 vs 26%) in
Pakistan [52]. Although 49% efficacy is unacceptably low,
this does suggest that CQ resistance is dose dependent in
P. falciparum with pfcrt 72–76 SVMNT. Similarly, treat-
ment with 50 mg/kg compared to 25 mg/kg over three
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CQ in P. falciparum with pfcrt 72–76 CVIET in West Af-
rica [55]. It may therefore be worth considering whether
increasing the dose and treatment duration of CQ can im-
prove the efficacy of CQ in India. This is potentially inter-
esting as considerably higher CQ doses given for longer
periods can be well tolerated [56,57]. However, it is not
known to what degree efficacy could potentially be im-
proved with a higher dose regimen.
The finding of only one pfmdr1 gene copy number in
all but one sample indicates that P. falciparum in Ujjain
do not presently have reduced susceptibility to artemis-
nin derivatives, lumefantrine, piperaquine or mefloquine
[31]. However, in transfection experiments pfmdr1 al-
leles S1034, N1042 and D1246 have been linked to re-
duced mefloquine and artemisinin sensitivity [29]. Thus
the P. falciparum population in Ujjain have pfmdr1 alleles
that possibly are linked to reduced artemisinin sensitivity.
The lack of pfmdr1 amplifications and high prevalence of
pfcrt 76 T suggests that artemether-lumefantrine would be
efficacious in Ujjain.
The pfnhe1 ms4760-6 haplotype that has two DNNND
repeats and one DDNHNDNHNND repeat was predom-
inant in Ujjain. In other studies in Asia the ms4760-7
haplotype that has three DNNND repeats and one
NHNDNHNNDDD repeat has been the most preva-
lent [38,39,58]. Both these profiles have been found to
have similarly reduced quinine sensitivity, suggesting
that P. falciparum with a degree of reduced quinine
sensitivity is prevalent in Ujjain [39]. However, the pfmdr1
86, 1034, 1042 and 1246 NSND haplotype that was highly
prevalent in Ujjain has been associated with quinine sensi-
tivity [29,59]. Also, none of the above is a marker of quin-
ine treatment failure and the correlation with quinine
susceptibility is not fully elucidated. Thus, available data
are difficult to interpret but provide a baseline for future
monitoring.
The principle limitation of this study is the relatively
small sample size. However, there was no obvious bias in
sample collection and the data are therefore probably rep-
resentative of the study area. There is also a lack local
knowledge about the correlation between the various mo-
lecular markers studied and reduced drug susceptibility.
However, the principle CQ and SP resistance markers
studied have been verified in clinical studies in India and
found to be valid.
Conclusions
This is the first report on anti-malarial resistance-associated
SNPs among P. falciparum field isolates in Ujjain, Madhya
Pradesh, central India, collected prior to the introduction of
ASP. The results indicate that the efficacy of standard dose
CQ was likely to be poor whereas ASP was likely to be effi-
cacious supporting the shift from CQ to ASP as first lineanti-malarial drug for uncomplicated P. falciparum malaria.
However, P. falciparum with reduced susceptibility to SP is
highly prevalent, highlighting the need for continuous sur-
veillance of ASP efficacy.
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